Trial Profile

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Acronyms CoBRIM-B

Most Recent Events

04 Apr 2016 According to ClinicalTrials.gov status changed from recruiting to discontinued due to slow accrual.
23 Jun 2015 Status changed from not yet recruiting to recruiting, according to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology
29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com